Kumar V, Sharma A
Department of Microbiology, Panjab University, Chandigarh, India.
J Chemother. 2008 Dec;20(6):672-83. doi: 10.1179/joc.2008.20.6.672.
Sepsis is complex clinical manifestation of an organism's overwhelming and unregulated immune response to infection. Despite more than 25 years of extensive research, sepsis and systemic inflammatory response syndrome (SIRS) remain the major causes of death in hospital intensive care units (ICUs). The mortality rate associated with sepsis varies from 30% to 70%. Up to now no specific treatment for sepsis exists, so in order to lower mortality rates associated with sepsis, it is important to search for better targets for treatment. The understanding of immunopathogenetic mechanisms involved in sepsis development has provided significant advances in the field of innate immunity, which plays an important role in the onset of sepsis and associated mortality. Not only have the pathways involved in sepsis development been defined but also various targets that can be used as an immunomodulatory approach during sepsis treatment. This review explores the role of innate immunity in the development of sepsis and its modulation as a future immunomodulatory approach for sepsis treatment.
脓毒症是机体对感染产生的强烈且失控的免疫反应所导致的复杂临床表现。尽管经过了25年多的广泛研究，但脓毒症和全身炎症反应综合征（SIRS）仍然是医院重症监护病房（ICU）的主要死亡原因。与脓毒症相关的死亡率在30%至70%之间。到目前为止，尚无针对脓毒症的特效治疗方法，因此为了降低与脓毒症相关的死亡率，寻找更好的治疗靶点至关重要。对脓毒症发生过程中免疫发病机制的理解在固有免疫领域取得了重大进展，固有免疫在脓毒症的发病及相关死亡率中起着重要作用。不仅明确了脓毒症发生所涉及的途径，还确定了多种可在脓毒症治疗期间用作免疫调节方法的靶点。本综述探讨了固有免疫在脓毒症发生中的作用及其调节，作为脓毒症治疗未来的免疫调节方法。
